Botulinum toxin type A therapy for blepharospasm – Update of a Cochrane systematic review and meta-analysis
Objective: To compare the effects of botulinum toxin type A (BtA) versus placebo in blepharospasm. Background: This is an update of a Cochrane systematic review.…Alternating hemiplegia of childhood: Movement disorders and epilepsy due to mutuations in ATP1A3
Objective: To present 2 cases of children with genetic confirmative test of alternating hemiplejia of childhood. Background: Alternating hemiplegia of childhood (AHC) is a dominant…Physical therapy, a third wheel in the management of Parkinson’s disease
Objective: To reinforce the importance of physical therapy in the management of Parkinson's disease. Background: Unsteadiness, falling, and tendency to fall are frequent symptoms of…Finding an optimal lead trajectory for a better stimulated volume in movement disorder therapy
Objective: Defining the best lead trajectory (Arc; Ring) with a computational 3D stereotactic model of the Globus Pallidus internus (GPi) and investigating the influence of…EEG Spectral power changes prior to non-epileptic seizures: A pilot study
Objective: To assess possible EEG spectral power changes prior to psychogenic non-epileptic seizures (PNES) and identify whether a “positive marker” of PNES may exist. Background:…A rapid chemical-genetic screen utilising impaired movement phenotypes in caenorhabditis elegans
Objective: Development of a fast and unbiased screening method to identify C. elegans mutants with movement disabilities and drugs to improve impaired locomotion. Background: Identifying…Adult onset Niemann-Pick type C: 24 month follow-up on miglustat
Objective: To present a rare case of adult onset NPC patient and pointing out varying response of her distinct symptoms on long term follow up…Amelioration of αLPHA-synuclein aggregation and motor behavior deficits by apocyanin in intranigral lipopolysaccharide induced animal model of Parkinson’s disease
Objective: The present study evaluated the therapeutic potentials of apocyanin for the treatment of neurobehavioral consequences in LPS induced PD model. Background: Parkinson's disease (PD),…May early introduction of dopaminergic agonists improve simptoms after ischemic stroke? The interim report
Objective: To evaluate the effect of bromocriptine on motor impairment, functional disabilit and cognitive impairment 5, 10, and 15 of bromocriptine therapy in patients with…Creativity related to dopaminergic treatment. A multicenter study
Objective: To study patients with Parkinson´s disease (PD) and enhanced creativity related to dopaminergic therapy. Background: Impulse control disorders (ICD) including pathological gambling, hypersexuality, and…
- « Previous Page
- 1
- …
- 113
- 114
- 115
- 116
- 117
- …
- 207
- Next Page »